Background: A previous randomized phase II study demonstrated that the addition of a c-Met inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib might prolong progression-free survival (PFS) in patients with previously treated, nonsquamous nonsmall-cell lung cancer (NSCLC). On a subset analysis, the survival benefit was greater in patients with wild-type EGFR (WT-EGFR) than in those with activating EGFR mutations. Herein, this phase III study compared overall survival (OS) between Asian nonsquamous NSCLC patients with WT-EGFR who received erlotinib plus tivantinib (tivantinib group) or erlotinib plus placebo ( placebo group).
introduction Lung cancer is one of the most common malignancies in the world, with an estimated annual incidence and mortality in eastern Asia of 650 000 and 550 000, respectively [1] . Histologically, ∼80% of lung cancer is nonsmall-cell lung cancer (NSCLC). Platinum-based chemotherapy is currently the firstline treatment of advanced or recurrent NSCLC without driver mutations in epidermal growth factor receptor (EGFR). Although many options are available for second-and third-line treatment of NSCLC, the effects of these therapies are modest, with a 5-year survival rate of 14%-16% [2] .
EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed for the treatment of NSCLC and are particularly effective against NSCLCs harboring driver mutations in EGFR, such as the exon 19 deletion or L858R mutation. The effect of EGFR-TKIs in NSCLC patients with wild-type EGFR (WT-EGFR) remains controversial, but several guidelines recommend EGFR-TKIs as an option of second-line treatments for NSCLC patients with WT-EGFR [3] . Although it was a retrospective analysis with limited number of samples (n = 197), BR.21 study suggested that the survival benefit derived from treatment with the EGFR-TKI erlotinib is not only limited to the patients with EGFR driver mutations [4] .
The receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor (HGF), are overexpressed in many types of cancers and may be associated with cell proliferation, inhibition of apoptosis, and metastasis [5] . Activation of the c-Met signaling pathway has been observed in NSCLC, regardless of EGFR mutation status, and correlates with poor outcomes [5] . Tivantinib (also known as ARQ 197) is a selective, oral, non-ATP-competitive, small-molecule inhibitor of c-Met. A Western phase II study suggested the clinical benefits of tivantinib combined with erlotinib in patients with previously treated NSCLC, including the adjusted progression-free survival [PFS; hazard ratio (HR) 0.68, P = 0.038, in the intent-to-treat (ITT) population] [6] . Furthermore, a subset analysis showed the benefit in adjusted overall survival (OS; HR 0.58, P = 0.04) in patients with nonsquamous cell histology [6] .
The dose of tivantinib used in the ARQ 197-209 [6] and the western phase III MARQUEE studies [7] was 360 mg b.i.d. and was not adjusted for polymorphisms of CYP2C19, the key enzyme responsible for metabolizing tivantinib. Western populations mainly comprise CYP2C19 extensive metabolizers (EMs) with at least one allele of wild-type CYP2C19. The proportion of CYP2C19 poor metabolizers (PMs) who are homozygotes of functionally deficient CYP2C19 polymorphisms is ∼20% in Asians, while only 3% in Caucasians [8] . Previous Japanese phase I studies (ARQ 197-003 and ARQ 197-005) evaluated the safety of tivantinib plus erlotinib in NSCLC and found hematological toxicities to be the most common treatment-related adverse events (AEs), regardless of CYP2C19 status [9] . These studies concluded that 360 mg b.i.d. and 240 mg b.i.d. are the recommended doses of tivantinib in combination with erlotinib for Asian EMs and PMs, respectively [9] .
patients and methods
study design
This was a multicenter (41 centers in Japan, 13 in Korea, and 8 in Taiwan, supplementary Table S1 , available at Annals of Oncology online), randomized, double-blind Asian phase III study (ATTENTION study, NCT01377376). Patients were randomized in a 1:1 ratio to receive either erlotinib plus tivantinib (tivantinib group) or erlotinib plus placebo ( placebo group). The randomization was stratified according to a dynamic allocation procedure to balance the treatment groups within the following baseline factors; CYP2C19 phenotype, the number of prior therapies, country, smoking history, and disease status (advanced or recurrent). The patients, investigators, and sponsor were blinded to the treatment assignment until 380 or more events were observed or the study was terminated for any reason. The dose of tivantinib was based on pretreatment testing for CYP2C19 genotype: EMs received 360 mg b.i.d. and PMs received 240 mg b.i.d. [9, 10] . Tivantinib and placebo capsules were supplied by the sponsor and orally administered during or immediately after meals. Regardless of CYP2C19 phenotype, 150 mg of erlotinib was administered once daily ≥1 h before or ≥2 h after a meal. Patients continued the study treatments until they met discontinuation criteria, including disease progression and safety concerns. After treatment ended, OS was confirmed every 12 weeks.
Assuming an accrual period of 18 months, a follow-up period of 12 months for the last patient, and a dropout rate of 5%, we estimated that a total of 460 patients (230 per group) would yield at least 80% power at a twosided significance level of 0.05. This estimation was based on a median OS of 8 months for patients treated with erlotinib plus placebo [11] and HR of 0.75 for the comparison of the tivantinib group with the placebo group [12, 13] .
This study was conducted in accordance with institutional guidelines, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients provided written informed consent. The sponsor consulted the Safety Review Committee (SRC) as required, and the SRC provided recommendations, including continuation, temporary interruption, or termination of the study. eligibility criteria. The major inclusion criteria were; age ≥20 years, Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1, histologically or cytologically confirmed stage IIIB/IV nonsquamous NSCLC, WT-EGFR defined as EGFR with neither exon 19 deletion nor exon 21 L858R mutation, having received one or two prior regimens of systemic anticancer therapy for NSCLC, one of which had to be platinum-based. Detailed eligibility criteria are shown in supplementary data, available at Annals of Oncology online. patient evaluations. Baseline evaluations included vital signs, blood counts, serum biochemistry, electrocardiograms, genotyping of CYP2C19, and tumor evaluation. Vital signs, blood counts, and serum biochemistry were assessed every week for the first 4 weeks and every 2 weeks thereafter. Electrocardiography was carried out every 4 weeks. Tumor response was radiologically evaluated on days 29 and 57 and every 8 weeks thereafter according to the Response Evaluation Criteria in Solid Tumors, version 1.1. AEs were assessed continuously throughout the study and graded according to the Common Terminology Criteria for Adverse Events, version 4.0.
statistical analysis
The primary objective was to compare OS between the two treatment groups in the ITT population. OS was defined as the time from the date of randomization to the date of death from any cause. Patients who survived until the cutoff date or who were lost to follow-up were censored at the last confirmed survival date. OS was compared between treatment groups using the stratified log-rank test, adjusting for CYP2C19 phenotype, number of prior therapies, and country as stratification factors to obtain point estimates of the treatment HR and 95% confidence interval (CI). Median OS was estimated by the Kaplan-Meier method for each treatment group, and the corresponding 95% CIs were calculated. In addition, a stratified Cox proportional hazard regression model was employed for multivariate analyses. 
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Secondary end points were PFS, objective response rate, disease control rate, and safety. PFS was defined as the time from the date of randomization to the date of either disease progression or death from any cause. Tumor response was evaluated by an Independent Review Committee. Exploratory end points included pharmacokinetic and predictive biomarkers, including c-Met expression, HGF expression, c-Met copy number, serum HGF level, and plasma vascular endothelial growth factor level. Blood samples for pharmacokinetics were obtained as described in supplementary Figure S1 , available at Annals of Oncology online. The methods for determining the predictive biomarker was described in supplementary data, available at Annals of Oncology online.
results

patients and treatment
In August 2011, the ATTENTION study began enrollment with a target of 460 patients. In October 2012, the study was prematurely terminated by the sponsor, following the SRC recommendation based on deaths from interstitial lung disease (ILD). At study termination, a total of 307 patients had been randomly assigned, and 303 patients had received study drugs ( Figure 1 ). The SRC recommended termination of new enrollment, but allowed the enrolled patients to continue tivantinib plus erlotinib or erlotinib alone (without placebo) in an unblinded manner if they were informed and consented to the risk of ILD and their investigators claimed that the benefits of continued treatment would outweigh the risks.
By data cutoff in September 2013, 300 patients had withdrawn from the study, and 7 patients were still receiving the study treatment ( Figure 1 ). Demographic and baseline characteristics of randomized patients were well balanced between the groups ( Table 1 ). The median treatment duration was 1.9 months (range, 0.1-24.9 months) in the tivantinib group and 1.5 months (range, 0.1-12.8 months) in the placebo group. The median follow-up in both groups was 11.2 months (range, 0.3-25.7 months).
efficacy Median OS was 12.7 months (95% CI 10.0-15.7 months) in the tivantinib group and 11.1 months (95% CI 9.5-12.6 months) in the placebo group (HR, 0.891; 95% CI 0.670-1.185; stratified log-rank P = 0.427, Figure 2A ). Median PFS was 2.9 months in the tivantinib group and 2.0 months in the placebo group (HR, 0.719; 95% CI 0.543-0.954; stratified log-rank P = 0.019, Figure 2B ). Given the increased probability of type I error due to multiplicity, the P value of PFS (P = 0.019) should be interpreted cautiously in this study.
The HR for OS by each predictive biomarker is summarized in Figure 3 . The HR for nearly all markers favored the tivantinib group. Tivantinib was associated with a significant OS benefit in patients with high HGF expression, defined as an H score of ≥200 on IHC and in those with normal copy number of c-Met, defined as a copy number of <4. In addition, favorable effect on OS was also observed in patients with high serum HGF concentration, KRAS mutation, and CYP2C19 PM. Similar trends were observed in the HR for PFS (supplementary Figure S2, 
safety
The commonly (>20% of patients) observed AEs in any-grade were rash, diarrhea, dry skin, anorexia, stomatitis, and nausea, regardless of the placebo and the tivantinib group. As the common grade ≥3 AEs, hematological toxicities such as neutropenia, leukopenia, febrile neutropenia, and anemia were more frequently and severely developed in the tivantinib group than the placebo group (Table 2) . Among the tivantinib group, such hematological toxicities were more frequently found in PMs (Table 2) . At the time of data cutoff, ILD had occurred in 20 patients according to the investigator assessment. The overall incidence of any-grade ILD was 9.2% (14 cases) with 3 cases leading to death in the tivantinib group, and 4.0% (6 cases) with no related mortality in the placebo group. In the tivantinib group, incidences of ILD appeared similarly in each country, while PMs appeared to show lower incidence than EMs (supplementary Figure S1 , available at Annals of Oncology online).
discussion
This ATTENTION study of tivantinib was aimed to confirm whether the results of the phase II study (ARQ 197-209) are applicable to the Asian NSCLC population, which differs from the non-Asian population in two important respects [6] . First, the incidence of EGFR driver mutations is higher in Asian NSCLC (32% in Asians versus 7% in non-Asians) [14] . A subanalysis of the ARQ 197-209 study demonstrated that the addition of tivantinib to erlotinib resulted in a trend toward prolonged PFS and OS compared with erlotinib alone in previously treated patients with NSCLC. However, these trends were more clearly observed in patients with WT-EGFR. Nowadays, erlotinib alone has very little role in patients with WT-EGFR [15, 16] , but it was indicated as a reasonable control agent for second-line treatment of WT-EGFR, according to the guideline of the time when this study started [3] . Second, the incidence of CYP2C19 PMs is higher in Asians (20% in Asians versus 3% in Caucasians) [8] . Phase I studies in Japanese patients proposed a lower recommended dose of tivantinib for CYP2C19 PMs (240 mg) than for EMs (360 mg) [9, 10] . On the basis of these findings, we excluded patients with mutated EGFR from the ATTENTION study and carried out pretreatment testing for CYP2C19 polymorphisms to determine the initial dose of tivantinib. Our results indicated that the addition of tivantinib to erlotinib did not improve OS, but prolonged PFS in this population. Although the ATTENTION study was smaller (n = 307) than the MARQUEE study (n = 1048), our results showed similar trends to the MARQUEE study, suggesting that our study design was appropriate for the Asian population [7] . The most common grade ≥3 toxicities in the tivantinib group were hematologic toxicities, similar to previous studies. The frequencies of grade ≥3 neutropenia in both EMs and PMs were higher than that in Western studies (Table 2) [6, 7] . In contrast, the most common toxicities in the placebo group were the nonhematologic reactions of rash, diarrhea, and dry skin, which are the well-known AEs related to erlotinib as a single agent [17] . The tivantinib group had nearly the same incidences and severities of these nonhematologic toxicities, indicating that the addition of tivantinib did not exacerbate such erlotinib-related toxicities, with the exception of ILD. In this ATTENTION study, the incidence of ILD was 9.2% (n = 14 of 152) in the tivantinib group and 4.0% (n = 6 of 151) in the placebo group. The increased incidence of ILD in the tivantinib group was observed in Korean and Taiwanese, as well as did in Japanese. Historically, 4.0%-5.8% of Japanese patients with NSCLC developed ILD when treated with EGFR-TKI as a single agent [18, 19] . Those facts suggested that tivantinib plus erlotinib may increase the risk of ILD, at least in this study population. It is of note that ILD has not been associated with tivantinib monotherapy in Asian phase I/II studies of patients with lung cancer (n = 25), hepatocellular carcinoma (n = 28), gastric cancer (n = 34), or other solid cancers (n = 18) [10, 20, 21] . These results suggest that tivantinib alone might not directly elicit ILD, but may increase the risk of ILD caused by erlotinib. It is suggested that the combination of tivantinib and erlotinib should not be pursued in Asian nonsquamous NSCLC patients with WT-EGFR further, unless we will invent an approach to improve the risk/benefit balance of this combination by identifying a predictor of both longer survival and the risk of ILD. The biomarker analysis of this study demonstrated that high HGF expression is most likely to be a predictor for longer survival by this combination (Figure 3) . However, predictors of the risk of ILD were not suggested in this study. The known risk factors for ILD in NSCLC patients treated with EGFR-TKIs were older age, poor performance status, male sex, smoking history, pre-existing pulmonary fibrosis, and concurrent cardiac disease [19] . As shown in supplementary Table S4 , available at Annals of Oncology online, the subjects who developed ILD were apparently not biased toward any known risk factor for ILD. To our knowledge, this is the first phase III study by dosing according to polymorphism of metabolizing enzyme. Such way of dosing might be considerable particularly for agents with relatively narrow therapeutic window. In this study, even though CYP2C19 PMs received lower dose (240 mg b.i.d.) of tivantinib than EMs did (360 mg b.i.d.), PMs resulted in a trend of longer OS and PFS, higher incidence of grade ≥3 neutropenia, and higher concentration of plasma tivantinib. These results may support that lower dose of tivantinib in CYP2C19 PMs was largely sufficient. Differently from these trends, it is of interest that the incidence of ILD was lower in PMs than in EMs. It is unclear whether this lower incidence in PMs could be explained by chance or not.
In summary, although this study lacked statistical power because of premature termination and did not demonstrate an improvement in OS, the results of our study suggest that tivantinib combined with erlotinib might improve PFS than erlotinib alone in nonsquamous NSCLC patients with WT-EGFR. The risk of ILD in Asian patients was higher for patients receiving tivantinib plus erlotinib than in those receiving erlotinib alone. Ideally, biomarkers should be developed to identify subgroups of patients in whom the expected benefits of combining tivantinib with erlotinib would outweigh potential risks.
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